Abstract

Recurrent aphthous stomatitis (RAS) is a chronic, ulcerative condition of the oral mucosa that affects 10–25% of the population. The etiopathogenesis of the disease is not fully understood, although a polygenic mode of inheritance and immunological dysregulation have been suggested in several studies. The contribution of numerous predisposing factors, such as a deficiency of iron, vitamin B12 or folic acid, trauma, emotional stress, endocrine disturbances, or allergy, have also been considered. So far, no causative treatment for RAS has been developed; instead, topical and systemic drugs are used to reduce pain and inflammation, and to lengthen the period of remission.

Low-level laser therapy (LLLT) is a non-invasive and atraumatic therapeutic method that involves the local application of a high-density, monochromatic, narrow-band light source. With the use of the appropriate power and wavelength, the therapy brings anti-inflammatory and analgesic results, and wound healing is promoted. Several reports on the beneficial effects of LLLT in RAS have been presented recently.

This report describes 2 cases of adult patients with RAS treated with LLLT to relieve pain and promote the healing of the ulcers. The clinical presentations with the signs and symptoms are discussed and illustrated, along with the treatment algorithms and outcomes.

Key words: oral mucosa, low-level laser therapy, aphthous stomatitis

Clinical cases

Low-level laser therapy (LLLT) in the treatment of recurrent aphthous stomatitis (RAS) – a promising treatment option: A report of two cases
Introduction

Recurrent aphthous stomatitis (RAS; aphthae) is a common, painful, chronic inflammatory disease affecting up to 25% of the population, with a slightly higher prevalence in women and in groups of a higher socioeconomic status.1,2 The etiopathogenesis of RAS remains unclear, but an abnormal immune interaction within the oral mucosal cells caused by the impaired activation of the immune system in genetically predisposed subjects has been considered to be an essential contributor in this process.3–5 In aphthous lesions, the barrier function of the oral epithelium is destroyed. The exposure of danger-signal receptors, such as Toll-like receptors (TLRs), to pathogen- or microbial-associated (PAMP/MAMP) and damage-associated (DAMP) molecular patterns leads to an acute inflammatory reaction with cytokine production in the epithelial cells.6 The possible modifiers of the immune system in RAS include various local and systemic factors, e.g., stress and anxiety, mineral and vitamin deficiencies, hematological disorders, viral and bacterial infections, food allergies, trauma, smoking, or even left- or right-handedness. Systemic diseases and medications have also been suggested as the potential triggers of RAS in several studies, although the results remain equivocal.5,7,8

Familial accumulation was observed in up to 40% of patients with RAS.3,9 The genetic risk factors determining an individual’s susceptibility to the disease include various DNA polymorphisms distributed in the human genome, especially those related to alterations in the metabolism of cytokines.5,10 Recent research has suggested that dysregulation in the production of defensins might be involved in the development of several oral pathologies, including those with an autoimmune background.6,11

Aphthous lesions may be associated with systemic diseases, such as Behçet’s disease, Crohn’s disease, HIV infection, anemia, cyclic neutropenia, and celiac disease.2,12 Recurrent aphthous lesions have been classified into 3 varieties: major (Sutton), minor (Mikulicz) and herpetiform ulcers. Minor aphthae present as yellowish, shallow, ovoid erosions surrounded by an erythematous halo smaller than 5 mm in diameter. They heal within 10–14 days and are typically located on the non-keratinized oral mucosa (the floor of the mouth and the labial or buccal mucosa). Major aphthae appear as deep ulcers, larger than 10 mm in diameter, which heal within 6 weeks, sometimes leaving a scar. The lesions are painful and show a predilection for the soft palate, palatal fauces, lips, and tongue. Herpetiform aphthae are small (1–2 mm in diameter) and multiple (up to 100), occurring throughout the oral cavity and lasting for 7–10 days.1,2,13

The treatment of RAS is difficult and not always effective. The standard treatment regime includes the local application of steroids and non-steroidal anti-inflammatory drugs, together with agents which enhance epithelial regeneration. The therapy is mainly symptomatic and may lead to several side effects, including steroid-induced candidiasis. No effective causal treatment option is currently available.1,2,12,13

Low-level laser therapy (LLLT) involves the use of photons with non-thermal irradiance to alter biological activity. It is a non-invasive and atraumatic therapeutic method that involves the local application of a high-density, monochromatic, narrow-band light source. The main medical usage of LLLT is for pain and inflammation reduction, promoting the regeneration of different tissues and preventing damage to tissues. With the use of the appropriate power (from 5 to 200 mW) and wavelength (630–680 nm, 700–830 nm or 900 nm), the therapy brings anti-inflammatory and analgesic results and wound healing is promoted.14,15 The mechanism of action of LLLT may be very beneficial in the treatment of oral erosions and ulcers. There are few reports on accelerated healing in erosive mucocutaneous disorders and they are often presented as case series rather than large randomized clinical trials (RCTs). The effects on skin wound healing and periodontal inflammation management with laser biostimulation suggest that this treatment modality may also be useful for oral erosive conditions.16,17

This report describes 2 adult patients with RAS treated with LLLT to relieve pain and promote the healing of the ulcers. The clinical presentations with the signs and symptoms are discussed and illustrated, along with the treatment algorithms and outcomes.

Case reports

Case 1

A 25-year-old, generally healthy woman reporting no detrimental habits was admitted to the Department of Gerodontology and Oral Pathology of the Poznan University of Medical Sciences, Poland, with 2 painful ulcers on her tonsil and palatoglossal arch, which had developed 3 days earlier. Informed consent for examination was obtained from the patient as part of a routine protocol. According to the patient, the condition was recurrent, with flare-ups at 2–3-month intervals. The 1st episode appeared approx. 10 years earlier, and was exacerbated in the period 2009–2011, when she received orthodontic treatment with a fixed appliance. It was previously diagnosed as RAS by a general dentist. Usually, 1 or 2 major aphthae would appear simultaneously during a flare-up. The treatment of the previous lesions included a coating ointment composed of protein-free dialysate of calf blood and policresulen, which was not satisfactory for the patient. Upon admission, the patient suggested stress and tiredness as the cause for the lesions to recur.
On examination, 2 ulcers with an erythematous halo and fibrous coating, 2 cm in diameter, were revealed on the left tonsil and on the left palatoglossal arch (Fig. 1). The other regions of the oral mucosa were unaffected. The lymph nodes were normal. Because of the unfavourable location of the lesions and their large size, laser therapy was suggested. Low-level laser therapy was applied with a diode laser (DiodeLX, SMART M; Lasotronix, Piaseczno, Poland) set to a wavelength of 635 nm, a spot size of Ø 8 mm, a power of 100 mW, and an energy fluency of 4 J/cm² in continuous mode for 20 s per lesion (Fig. 2). It was administered 3 times – on the 1st, 3rd, and 4th day of the therapy. A baseline complete blood count (CBC) test performed on the day of the 1st visit showed no abnormalities. After the 1st session, the ulcers were less painful and the process of healing was evident (Fig. 3). After 3 sessions, the lesions were painless and the patient reported faster healing than during the previous episodes of RAS (Fig. 4).

Case 2

An 81-year-old woman suffering from hypertension and type 2 diabetes (T2D) was admitted to the Department of Gerodontontology and Oral Pathology of the Poznan University of Medical Sciences, Poland, with a complaint of painful lesions in the oral cavity which interfered with eating and speaking. Informed consent for examination was obtained from the patient as part of a routine protocol. The duration of the disease was 6 months with regular periods of remission and exacerbation. The patient had previously been treated by an otorhinolaryngologist and a general practitioner with topical choline salicylate, chlorhexidine mouth rinses and herbal extracts without satisfactory results. The CBC test results from the general outpatient clinic showed no abnormalities according to the patient.

Clinical examination revealed numerous minor aphthous erosions of the oral mucosa located on the buccal, labial, palatal, vestibular, gingival, tonsillar, and uvular surfaces (Fig. 5). Based on the anamnesis and the characteristic presentation of lesions, a diagnosis...
of RAS was established. Low-level laser therapy was administered with a diode laser (SMART M; Lasotronix) set to a wavelength of 635 nm, a spot size of Ø 8 mm, a power of 100 mW, and an energy fluency of 4 J/cm² in continuous mode for 20 s per lesion a total of 3 times – on the 1st, 2nd and 4th day of treatment, as presented in Fig. 5.

Additionally, a topical steroid and a coating salve were prescribed and applied to the available surfaces.

After the 1st session, the patient claimed that her pain had lessened and after 3 sessions, a significant improvement in her clinical condition was observed (Fig. 6).

Discussion

Although several multi-center studies have been performed worldwide, the etiology of RAS remains elusive and only non-specific, symptomatic treatment is currently available. Pain management in RAS is a challenge in oral medical practice. A typical treatment algorithm begins with excluding systemic diseases and correcting any predisposing factors, such as nutritional deficiencies. Treatment options include non-steroidal and steroidal agents, antibiotics to prevent secondary infections, analgesic drugs, and coating films. Topical corticosteroids, which are widely used in immune-mediated oral diseases, eliminate pain and shorten the healing time, although they may induce acute pseudomembrane candidiasis in non-immunocompetent patients, e.g., those who suffer from diabetes mellitus or are HIV-positive. Mouthwashes containing tetracycline or chlorhexidine may reduce ulcer duration, although they may also cause tooth discoloration and are contraindicated in children. A topical coating salve prevents the irradiation of the lesions. Low-level laser therapy may be successfully administered as a non-invasive method to patients with large aphthous ulcers to accelerate the healing process.

The cases described in this paper demonstrated the analgesic and healing-promoting effect of LLLT as the only therapy and in combination with a topical steroid and a coating salve.

Several articles describing the effects of laser therapy in patients with RAS and lichen planus (LP) have been published in recent years. Diode, Nd:Yag and CO₂ lasers have been used in trials. The beneficial effects of LLLT with diode lasers which have been reported in RCTs on RAS include immediate pain reduction and a shorter healing time in comparison with placebo groups. Moreover, De Suoza et al. reported the faster regression of lesions when using LLLT than in patients treated with corticosteroids (4 days vs 5–7 days). In 2 case series presented by Anand et al. and Gandhi Babu et al., pain relief and faster healing times were reported, compared to previous episodes, by all RAS subjects who underwent diode laser stimulation. Recent studies performed by Lalabonova and Daskalov revealed a greater efficacy of LLLT as compared to conventional pharmacotherapy in reducing pain and the symptoms of inflammation and in promoting healing and epithelialization. Albrektson et al. showed the analgesic effect of LLLT after the 1st session, with the effect persisting for up to 3 days according to the visual analog scale (VAS). Patients also reported pain relief while eating, drinking and tooth brushing. On the other hand, Jijin et al. presented similar results for both LLLT and amlexanox – a topical anti-inflammatory and anti-allergic drug. Likewise, Kashmoola et al., who examined 47 RAS subjects in Iraq, did not observe significant differences in the healing time between the experimental groups and the controls. Attempts to manage RAS with CO₂ lasers...
in a non-contact, non-ablative manner, where the mucosa was protected from the heat produced by the laser with a thick layer of a transparent gel, also resulted in significant pain reduction with a sustained analgesic effect and accelerated healing process.\textsuperscript{16,17,20} The use of Nd:Yag laser stimulation in 2 RCTs resulted in pain relief and a faster healing time in the experimental group as compared to the controls\textsuperscript{29} and led to a significant analgesic effect in the experimental group.\textsuperscript{30} The diversity of LLLT parameters used in many of the studies, including treatment dosage, wavelength, exposure time, or tissue type, prevents an unambiguous interpretation of the results.

Pain reduction and the acceleration of healing in the case of recurrent flare-ups are extremely relevant to the quality of life of patients with RAS. Further studies are required to define the efficacy of LLLT in the treatment of RAS in comparison to more traditional, anti-inflammatory treatment modalities.

\section*{Conclusions}

Low-level laser therapy may be considered an effective and non-invasive method of reducing symptoms and promoting the healing of aphthous ulcers in patients with RAS without addressing the cause. There is, however, still an urgent need to develop an effective, causative treatment for RAS.

\section*{ORCID iDs}

Maria Olejnik \(\text{https://orcid.org/0000-0003-3674-2179}\)

Zuzanna Ślebioda \(\text{https://orcid.org/0000-0002-5482-3964}\)

Barbara Dorocka-Bobkowska \(\text{https://orcid.org/0000-0003-3659-7761}\)

\section*{References}


